查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2011246

小鼠模型市场：按模型类型、应用和最终用户划分－2026-2032年全球市场预测

Mice Model Market by Model Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，小鼠模型市值将达到 17.4 亿美元，到 2026 年将成长到 18.8 亿美元，到 2032 年将达到 31.1 亿美元，复合年增长率为 8.66%。

主要市场统计数据
基准年 2025 17.4亿美元
预计年份：2026年 18.8亿美元
预测年份 2032 31.1亿美元
复合年增长率 (%) 8.66%

本文探讨了创新小鼠模型如何发展成为现代非临床研究框架内的重要资产。

生物医学研究的进步已将小鼠模型从单纯的实验标本提升为支持现代治疗方法发现的复杂平台。过去十年间，研究人员利用小鼠的遗传柔软性和生理有效性，以前所未有的精确度模拟了人类疾病。因此，这些模型已成为阐明分子路径、检验药物标靶和评估安全性的重要工具。

基因组编辑和人工智慧驱动的表型分析的重大进展如何重新定义临床前研究的范式。

受基因组编辑技术的突破、对转化准确性的需求以及减少使用高等哺乳动物的伦理压力等因素的推动，小鼠模型研究领域正经历着变革性的转变。 CRISPR-Cas9及相关基因编辑平台使得建立客製化基因敲除小鼠和人源化模型成为可能，从而缩短了研发週期并降低了成本。这些平台如今与先进的育种策略相结合，用于生产能够模拟复杂人类疾病特征的基因转殖小鼠。

2025 年美国贸易措施的影响以及如何应对对确保模式采购和业务永续营运。

美国将于2025年实施并提高关税，这不仅为小鼠模型生态系统带来了挑战，也带来了调整的机会。进口科研耗材和专有繁殖个体的关税增加了模型生产成本，迫使许多机构重新评估其供应链和供应商组合。研究机构和合约研究组织（CRO）正寻求透过整合订单、协商长期供应合约以及投资本地繁殖设施来减轻财务负担。

本研究旨在阐明模型物种的复杂性和应用主导的需求如何交织，并塑造独特的研究路径。

由于研究需求和资金优先事项各不相同，小鼠模型市场被细分为不同的类别，以满足特定的实验需求。近交系小鼠提供高度可重复的遗传背景，是基础研究的理想选择；而非近交系小鼠则引入了反映人类群体的异质性，并支持毒性评估。在基因工程领域，条件性基因敲除可实现时间和组织特异性控制；转基因小鼠表达外源基因用于通路分析；基因敲除模型透过完全去除基因来阐明基因功能；而人源化系统则模拟人类免疫动力学。

该评估了影响小鼠研究平台区域部署的区域研究生态系统和资金优先事项。

对区域趋势的分析揭示了美洲、欧洲、中东和非洲以及亚太地区在研究投资、基础设施和合作研究网络方面的细微差异。在美洲，健全的资金筹措体系和集中的生物技术中心正在促进垂直整合的供应倡议，从而实现先进小鼠模型的快速部署。北美研究联盟和政府主导的措施正在推动官民合作关係，并加速科技的实用化。

绘製推动小鼠模型创新发展的竞争生态系统图，该生态系统以技术领先地位和策略伙伴关係为特征。

这项竞争格局汇集了专业的动物繁殖设施营运商、基因工程先驱和综合服务供应商，他们都充分利用自身在技术整合、广泛的产品组合和全球影响力方面的优势。领先的实验动物供应商正在扩展其基因库，以涵盖稀有基因敲除和人源化品系，并辅以合约繁殖服务，从而实现快速扩充性和客製化的群体管理。

为相关人员制定策略指南方针，以增强临床前模型的韧性并加速创新

产业领导者应优先投资在地化养殖基础设施，以降低贸易风险并防止供应中断。建立具有可扩展能力的区域性畜牧中心可以缩短前置作业时间，并提高对突发研究计画的应对力。同时，促进与基因组编辑专家的合作可以简化针对特定治疗标靶的客製化模型开发流程。

详细介绍一个稳健的混合研究框架，该框架利用一手访谈和全面的二手资料检验。

我们的分析融合了多层次的调查方法，包括一手和二手资料收集、严格的检验以及三角测量。首先，我们仔细审查二级资讯来源，例如同行评审的文献、专利资料库、监管文件和行业白皮书，以确定基础背景并识别新趋势。

将洞察力融入协作创新和策略远见，以塑造小鼠研究模型的未来。

小鼠模型处于科学创新、伦理考量和商业性需求的交会点。基因组编辑、数位表型分析和区域投资策略等领域的不断发展趋势凸显了该市场瞬息万变的现状，既充满变革，也蕴藏着无限机会。积极应对供应链脆弱性并拥抱新兴技术的相关人员，将更有能力引领下一波临床前研究的突破性进展。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：小鼠模型市场：依模型类型划分

  • 基因改造小鼠模型
    • 条件性敲除模型
    • 人源化小鼠模型
    • 淘汰赛模特儿
    • 基因改造模型
  • 近交系小鼠模型
  • 非近交系小鼠模型

第九章：小鼠模型市场：依应用划分

  • 行为研究
  • 心血管疾病
  • 药物发现与毒理学
  • 遗传疾病调查
  • 免疫学
  • 感染疾病
  • 代谢性疾病
  • 神经系统疾病与神经退化性疾病
  • 肿瘤学研究

第十章：滑鼠模型市场：依最终使用者划分

  • 学术和研究机构
  • 合约研究组织（CRO）
  • 医院和诊断中心
  • 製药和生物技术公司

第十一章 小鼠模型市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 小鼠模型市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章：小鼠模型市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国小鼠模型市场

第十五章：中国小鼠模型市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Applied StemCell, Inc.
  • Aragen Life Sciences Ltd.
  • Biocytogen Boston Corporation
  • Charles River Laboratories International, Inc.
  • Creative Biolabs
  • Crown Bioscience by JSR Life Sciences, LLC
  • Cyagen US Inc. by PolyGene AG
  • Envigo by Inotiv, Inc.
  • GenOway
  • Harbour BioMed
  • inGenious Targeting Laboratory, Inc.
  • Janvier Labs
  • Marshall BioResources
  • MD Biosciences
  • Mirimus, Inc.
  • Ozgene Pty Ltd.
  • PhoenixBio Co., Ltd.
  • Shanghai Model Organisms Center, Inc.
  • Taconic Biosciences, Inc.
  • The Jackson Laboratory
  • TransCure bioServices
  • Translational Drug Development, LLC
  • Urosphere SAS
  • XenOPAT SL by Bellvitge Biomedical Research Institute
Product Code: MRR-4316E4E89369

The Mice Model Market was valued at USD 1.74 billion in 2025 and is projected to grow to USD 1.88 billion in 2026, with a CAGR of 8.66%, reaching USD 3.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.74 billion
Estimated Year [2026] USD 1.88 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 8.66%

Exploring how innovative murine systems have evolved to become indispensable assets in contemporary preclinical research frameworks

Advancements in biomedical research have elevated the role of murine systems from simple laboratory specimens to sophisticated platforms that underpin modern therapeutic discovery. Over the past decade, researchers have harnessed the genetic malleability and physiological relevance of mice to model human diseases with ever-increasing fidelity. As a result, these models have become indispensable tools for elucidating molecular pathways, validating drug targets, and assessing safety profiles.

In parallel, the proliferation of novel genetic engineering technologies has expanded the repertoire of available strains, enabling conditional gene expression, humanized immune responses, and tissue-specific knockouts. This convergence of technical innovation and unmet clinical needs has accelerated preclinical workflows, reshaping research priorities across academia, industry, and clinical settings. Consequently, an understanding of the current mice model landscape is essential for stakeholders seeking to navigate competitive pressures and align their research strategies with emergent trends.

How breakthroughs in genome editing and AI-powered phenotyping are redefining the preclinical research paradigm

The landscape of mice model research is undergoing transformative shifts driven by breakthroughs in genome editing, demand for translational accuracy, and ethical pressures to reduce higher-order mammalian use. CRISPR-Cas9 and related gene-editing platforms have democratized the creation of custom knockouts and humanized models, accelerating timelines and lowering costs. These platforms now coexist with advanced breeding strategies to yield genetically engineered mice that replicate complex human disease signatures.

Meanwhile, the integration of high-throughput phenotyping and in vivo imaging has enhanced the resolution at which researchers monitor disease progression and therapeutic efficacy. Artificial intelligence and machine learning algorithms have begun to sift through enormous data sets generated in these studies, offering predictive insights and facilitating the selection of optimal model types.

Ethical considerations and regulatory scrutiny have further influenced the market, prompting the implementation of rigorous welfare standards and incentivizing the development of alternative assays. As stakeholders navigate these dynamic forces, they must remain agile to leverage innovations that improve translational relevance and operational efficiency.

Navigating the ramifications of US trade measures in 2025 and their profound implications on model sourcing and operational resilience

The introduction and escalation of United States tariffs in 2025 have introduced both challenges and recalibration opportunities for the mice model ecosystem. Tariffs on imported scientific consumables and proprietary breeding stock have elevated costs for model generation, compelling many organizations to reassess their supply chains and vendor portfolios. Research institutions and Contract Research Organizations have sought to mitigate financial burdens by consolidating orders, negotiating long-term supply agreements, and investing in localized breeding facilities.

Despite these headwinds, the tariff environment has also galvanized domestic production capacity, as vendors expand in-country vivaria and streamline licensing processes to meet shifting demand. Consequently, collaborative networks have emerged between academic centers and biotechnology firms to share breeding resources and expertise, fostering resilience against trade uncertainties. Companies that adapt by diversifying sourcing strategies and embracing vertical integration stand to enhance supply security while maintaining rigorous standards of reproducibility.

Uncovering how model type intricacies and application-driven requirements converge to shape distinct research pathways

Diverse research imperatives and funding priorities have driven the segmentation of the mice model market into distinct categories that align with specific experimental needs. Inbred mice strains provide reproducible genetic backgrounds ideal for foundational studies, while outbred models introduce heterogeneity that mirrors human populations and supports toxicology assessments. On the genetically engineered front, conditional knockouts offer temporal and tissue-specific control, transgenic lines express exogenous genes for pathway analysis, knockout models elucidate gene function through full gene removal, and humanized systems recapitulate human immune dynamics.

Application segmentation reveals a broad spectrum of disease and therapeutic domains. Behavioral studies leverage specialized strains to probe neurological function, whereas cardiovascular research benefits from hypertensive and atherosclerotic models. Drug discovery and toxicology demand robust systems for early safety screening, and genetic disease research relies on congenital and metabolic disorder models. Immunology experiments are underpinned by humanized mice, infectious disease research exploits susceptibility variants, neurodegenerative inquiries utilize Alzheimer's and Parkinson's transgenics, and oncology investigations draw upon xenograft and syngeneic tumor systems.

End users range from academic and research institutions driving fundamental science to contract research organizations performing outsourced studies. Hospitals and diagnostic centers integrate preclinical findings into translational initiatives, while pharmaceutical and biotechnology companies depend on these models to advance pipelines from candidate identification through pre-IND safety assessment. Each segment presents unique requirements, procurement cycles, and validation standards that inform tailored service offerings.

Evaluating regional research ecosystems and funding priorities that drive differentiated adoption of murine research platforms

Regional dynamics reveal nuanced patterns in research investment, infrastructure, and collaborative networks across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, robust funding ecosystems and concentrated biotechnology hubs have cultivated vertically integrated supply chains, enabling rapid adoption of advanced mouse models. North American research consortia and government initiatives foster public-private partnerships that accelerate technology translation.

Across Europe, Middle East & Africa, stringent regulatory frameworks have elevated animal welfare standards, prompting synchronized adoption of refinement techniques and alternative validation methods. Strong academic clusters in Western Europe collaborate with biotech startups to co-develop bespoke strains, while emerging markets in the Middle East and Africa focus on capacity building and training to broaden regional expertise.

The Asia-Pacific region exhibits explosive growth fueled by rising research expenditure, expanding contract research organizations, and government incentives aimed at biotech innovation. China, Japan, and South Korea lead investment in state-of-the-art vivarium infrastructure, whereas Southeast Asian nations emphasize cross-border partnerships and talent development to meet escalating demand for translational models.

Mapping the competitive ecosystem defined by technological leadership and strategic alliances driving murine model innovation

The competitive landscape features specialized vivarium operators, genetic engineering pioneers, and comprehensive service providers that differentiate through technology integration, portfolio breadth, and global reach. Leading laboratory animal suppliers have expanded their genetic archives to encompass rare knockout and humanized lines, complemented by contract breeding services that offer rapid scalability and customized colony management.

Innovators of genome-editing tools have forged partnerships with pharmaceutical giants to co-develop disease models aligned with pipeline priorities, while full-service contract research organizations bundle model provision with in vivo efficacy and toxicological evaluation. Strategic collaborations between academic institutions and commercial entities have accelerated the commercial deployment of new strains, deepening the bench-to-bedside integration.

Companies that invest in digital platforms for colony management and integrate imaging-based phenotyping services have gained a competitive edge by unlocking data-rich insights and fostering reproducibility. As intellectual property considerations intensify, players with robust patent portfolios and licensing frameworks command premium positioning, particularly for next-generation humanized and conditional knockout models.

Outlined strategic directives empowering stakeholders to enhance resilience and accelerate preclinical model innovation

Industry leaders should prioritize investments in localized breeding infrastructure to mitigate trade-related risks and ensure uninterrupted supply. Establishing regional vivarium hubs with scalable capacity will reduce lead times and enhance responsiveness to emergent research projects. Meanwhile, fostering collaborations with genome-editing specialists can streamline the development of bespoke models that match therapeutic pipelines' unique targets.

Organizations must also capitalize on digitalization by adopting cloud-based colony management systems and AI-driven phenotyping platforms. These tools not only bolster data integrity but also accelerate decision-making processes through predictive analytics. Concurrently, proactive engagement with regulatory authorities and ethics committees will help organizations anticipate evolving welfare standards and streamline model approval pathways.

Finally, corporate research divisions, academic centers, and contract organizations should coalesce around consortia that share best practices, breeding resources, and phenotypic databases. Such collaborative networks will dilute operational costs, spur innovation, and cultivate a resilient infrastructure capable of adapting to geopolitical and technological shifts.

Detailing a robust hybrid research framework leveraging primary interviews and comprehensive secondary data validation

Our analysis integrates a multi-layered research methodology composed of primary and secondary data collection, rigorous validation, and triangulation. Initially, secondary sources were examined, encompassing peer-reviewed literature, patent databases, regulatory filings, and industry white papers to establish foundational context and identify emerging trends.

Subsequently, in-depth interviews with key opinion leaders across academia, contract research organizations, and biotechnology firms provided qualitative insights into operational challenges, adoption drivers, and innovation roadblocks. Data gleaned from these discussions underwent cross-verification against commercial intelligence platforms, vendor catalogs, and technical specifications to ensure consistency.

Quantitative data points were subjected to triangulation through comparative analysis of company disclosures, public grant databases, and import-export records. This multi-pronged approach enabled a balanced perspective that accounts for both macro-level influences and micro-level decision criteria. Findings were then synthesized into coherent narratives that reflect current market realities, future inflection points, and actionable intelligence.

Synthesizing insights on collaborative innovation and strategic foresight shaping the future of murine research models

Mice models stand at the confluence of scientific innovation, ethical considerations, and commercial imperatives. The evolving landscape of genome editing, digital phenotyping, and regional investment strategies underscores a market in flux-one characterized by both disruption and opportunity. Stakeholders who proactively address supply-chain vulnerabilities and adopt emerging technologies will be well-positioned to lead the next wave of preclinical breakthroughs.

The cumulative impact of trade policies, shifting funding landscapes, and rising demand for translational fidelity necessitates an agile approach to portfolio planning and infrastructure development. By aligning operational capabilities with cutting-edge scientific advances and regulatory requirements, organizations can ensure sustained relevance and competitive differentiation.

In sum, the trajectory of mice model research hinges on collaboration, innovation, and strategic foresight. Those who master these imperatives will unlock new avenues for therapeutic discovery, augment their research efficiency, and ultimately contribute to meaningful advancements in human health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Mice Model Market, by Model Type

  • 8.1. Genetically Engineered Mice Models
    • 8.1.1. Conditional Knockout Models
    • 8.1.2. Humanized Mice Models
    • 8.1.3. Knockout Models
    • 8.1.4. Transgenic Models
  • 8.2. Inbred Mice Models
  • 8.3. Outbred Mice Models

9. Mice Model Market, by Application

  • 9.1. Behavioral Studies
  • 9.2. Cardiovascular Diseases
  • 9.3. Drug Discovery & Toxicology
  • 9.4. Genetic Disease Research
  • 9.5. Immunology
  • 9.6. Infectious Diseases
  • 9.7. Metabolic Disorders
  • 9.8. Neurology & Neurodegenerative Diseases
  • 9.9. Oncology Research

10. Mice Model Market, by End User

  • 10.1. Academic & Research Institutions
  • 10.2. Contract Research Organizations (CROs)
  • 10.3. Hospitals & Diagnostic Centers
  • 10.4. Pharmaceutical & Biotechnology Companies

11. Mice Model Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Mice Model Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Mice Model Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Mice Model Market

15. China Mice Model Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Applied StemCell, Inc.
  • 16.6. Aragen Life Sciences Ltd.
  • 16.7. Biocytogen Boston Corporation
  • 16.8. Charles River Laboratories International, Inc.
  • 16.9. Creative Biolabs
  • 16.10. Crown Bioscience by JSR Life Sciences, LLC
  • 16.11. Cyagen US Inc. by PolyGene AG
  • 16.12. Envigo by Inotiv, Inc.
  • 16.13. GenOway
  • 16.14. Harbour BioMed
  • 16.15. inGenious Targeting Laboratory, Inc.
  • 16.16. Janvier Labs
  • 16.17. Marshall BioResources
  • 16.18. MD Biosciences
  • 16.19. Mirimus, Inc.
  • 16.20. Ozgene Pty Ltd.
  • 16.21. PhoenixBio Co., Ltd.
  • 16.22. Shanghai Model Organisms Center, Inc.
  • 16.23. Taconic Biosciences, Inc.
  • 16.24. The Jackson Laboratory
  • 16.25. TransCure bioServices
  • 16.26. Translational Drug Development, LLC
  • 16.27. Urosphere SAS
  • 16.28. XenOPAT SL by Bellvitge Biomedical Research Institute

LIST OF FIGURES

  • FIGURE 1. GLOBAL MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MICE MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MICE MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MICE MODEL MARKET SIZE, BY MODEL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MICE MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MICE MODEL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MICE MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MICE MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MICE MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MICE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MICE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MICE MODEL MARKET SIZE, BY CONDITIONAL KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MICE MODEL MARKET SIZE, BY HUMANIZED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MICE MODEL MARKET SIZE, BY HUMANIZED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICE MODEL MARKET SIZE, BY HUMANIZED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICE MODEL MARKET SIZE, BY KNOCKOUT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MICE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MICE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MICE MODEL MARKET SIZE, BY TRANSGENIC MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICE MODEL MARKET SIZE, BY INBRED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MICE MODEL MARKET SIZE, BY INBRED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICE MODEL MARKET SIZE, BY INBRED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MICE MODEL MARKET SIZE, BY OUTBRED MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MICE MODEL MARKET SIZE, BY OUTBRED MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MICE MODEL MARKET SIZE, BY OUTBRED MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MICE MODEL MARKET SIZE, BY BEHAVIORAL STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MICE MODEL MARKET SIZE, BY BEHAVIORAL STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MICE MODEL MARKET SIZE, BY BEHAVIORAL STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MICE MODEL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MICE MODEL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MICE MODEL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MICE MODEL MARKET SIZE, BY DRUG DISCOVERY & TOXICOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MICE MODEL MARKET SIZE, BY DRUG DISCOVERY & TOXICOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MICE MODEL MARKET SIZE, BY DRUG DISCOVERY & TOXICOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MICE MODEL MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MICE MODEL MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MICE MODEL MARKET SIZE, BY GENETIC DISEASE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICE MODEL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICE MODEL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MICE MODEL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MICE MODEL MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MICE MODEL MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MICE MODEL MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MICE MODEL MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MICE MODEL MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MICE MODEL MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MICE MODEL MARKET SIZE, BY NEUROLOGY & NEURODEGENERATIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MICE MODEL MARKET SIZE, BY NEUROLOGY & NEURODEGENERATIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MICE MODEL MARKET SIZE, BY NEUROLOGY & NEURODEGENERATIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MICE MODEL MARKET SIZE, BY ONCOLOGY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MICE MODEL MARKET SIZE, BY ONCOLOGY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MICE MODEL MARKET SIZE, BY ONCOLOGY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MICE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MICE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MICE MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MICE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MICE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MICE MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MICE MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MICE MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MICE MODEL MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MICE MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MICE MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MICE MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MICE MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS MICE MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MICE MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GCC MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. GCC MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. G7 MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. G7 MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 131. G7 MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NATO MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 136. NATO MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. NATO MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL MICE MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA MICE MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA MICE MODEL MARKET SIZE, BY MODEL TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA MICE MODEL MARKET SIZE, BY GENETICALLY ENGINEERED MICE MODELS, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA MICE MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA MICE MODEL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)